Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Subcutaneous Pembrolizumab (MK-3475A) in Advanced Solid Tumors
NCT05017012Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2021
- Primary completion
- May 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 6
01
Overview
Phase 1, open-label trial of pembrolizumab in solid tumor (4 arms), sponsored by Merck & Co. Primary endpoints: Pembrolizumab Trough Concentration, Pembrolizumab Maximum Plasma Concentration and 7 more. Started Sep 2021; status: completed.
02
Drugs
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05017012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05017012.